Results 1 to 10 of about 21,421 (178)

Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major [PDF]

Blood Advances
: Iron overload in transfusion-dependent β-thalassemia (TDT) generates reactive oxygen species, predisposing to post–hematopoietic stem cell transplant (HSCT) endothelial activation. Abatacept prevents acute graft-versus-host disease (GVHD) by inhibiting
Pooja Khandelwal, Azada Ibrahimova, Adam Lane, Michael Grimley, Stella M. Davies, Sonata Jodele   +5 more
doaj   +2 more sources

Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases

EClinicalMedicine, 2022
Summary: Background: Abatacept is a selective T-cell costimulation modulator approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis.
Jingjing Wang, Xin Zhang, Xiaozhen Geng, Juanjuan Shi, Xiaoli Jia, Shuangsuo Dang, Wenjun Wang   +6 more
exaly   +3 more sources

Abatacept

BioDrugs, 2006
Abatacept (Orencia) is the first in a new class of biologics known as selective costimulation modulators. It inhibits full activation of T cells and interacts with other cell types to affect additional mediators of the inflammatory cascade. The clinical efficacy of abatacept in patients with active rheumatoid arthritis, despite prior treatment with ...
Pauline S, Hervey, Susan J, Keam
europepmc   +10 more sources

First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis [PDF]

Journal of Comparative Effectiveness Research
Aim: To compare characteristics of patients with anticitrullinated protein antibody-positive (ACPA+) and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated abatacept or a tumor necrosis factor inhibitor (TNFi) as a first-line ...
Gordon Lam, Hanke Zheng, Andrew Klink, Vardhaman Patel, Emily Bland, Laetitia N’Dri, Parisa Asgarisabet, Keith Wittstock, Cherrishe Brown-Bickerstaff, Mark Chaballa, Vadim Khaychuk, Bruce Feinberg   +11 more
doaj   +2 more sources

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis

Rheumatology and Therapy, 2023
Introduction One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability.
Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Thomas W. J. Huizinga, Gustavo Citera, Clifton O. Bingham, Subhashis Banerjee, Benjamin P. Soule, Marleen Nys, Sean E. Connolly, Karissa L. Lozenski, Joe Zhuo, Robert Wong, Kuan-Hsiang Gary Huang, Roy Fleischmann   +14 more
doaj   +1 more source

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Arthritis Research & Therapy, 2023
Background AVERT-2 (a phase IIIb, two-stage study) evaluated abatacept + methotrexate versus methotrexate alone, in methotrexate-naive, anti-citrullinated protein antibody-positive patients with early (≤ 6 months), active RA.
Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W. J. Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Chun Wu, Sean E. Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski, Roy Fleischmann   +12 more
doaj   +1 more source

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

Arthritis Research & Therapy, 2021
Background To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials.
Teresa A. Simon, Lixian Dong, Kevin L. Winthrop   +2 more
doaj   +1 more source

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2022
Background Abatacept is a recombinant fusion protein composed of the extracellular domain of cytotoxic T-lymphocyte antigen 4 and the Fc portion of immunoglobulin (Ig) G. The mechanism of action of abatacept in rheumatoid arthritis (RA) is believed to be
Ryosuke Fukue, Yuka Okazaki, Takahisa Gono, Masataka Kuwana   +3 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain [PDF]

Farmacia Hospitalaria, 2014
Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous
R. Ariza, A. van Walsem, C. Canal, C. Roldán, L. Betegón, I. Oyagüez, K. Janssen   +6 more
doaj   +1 more source